Epidermal growth factor receptor (EGFR)-activating mutations occur in approximately 30% to 40% of patients with NSCLC [2], and for these patients EGFR tyrosine kinase inhibitors (TKI) are currently recommended as the standard first-line agents [3]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.